checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens 
immune system influences fate developing cancers functioning tumour promoter facilitates cellular transformation promotes tumour growth sculpts tumour cell immunogenicity- also extrinsic tumour suppressor either destroys developing tumours restrains expansion yet clinically apparent cancers still arise immunocompetent individuals part consequence cancer-induced immunosuppression many individuals immunosuppression mediated cytotoxic t-lymphocyte associated antigen ctla- programmed death pd two immunomodulatory receptors expressed t cells monoclonal-antibody-based therapies targeting ctla and/or pd checkpoint blockade yielded significant clinical benefits including durable responses patients different malignancies- however little known identity tumour antigens function targets t cells activated checkpoint blockade immunotherapy whether antigens can used generate vaccines highly tumour-specific use genomics bioinformatics approaches identify tumour-specific mutant proteins major class t-cell rejection antigens following anti-pd and/or anti-ctla therapy mice bearing progressively growing sarcomas show therapeutic synthetic long-peptide vaccines incorporating mutant epitopes induce tumour rejection comparably checkpoint blockade immunotherapy although mutant tumour-antigen-specific t cells present progressively growing tumours reactivated following treatment anti-pd and/or anti-ctla display overlapping mostly treatment-specific transcriptional profiles rendering capable mediating tumour rejection results reveal tumour-specific mutant antigens important targets checkpoint blockade therapy can also used develop personalized cancer-specific vaccines probe mechanistic 
